The REVIVE-IT Registry and Trial are designed to discover if advanced heart failure patients live longer and have a better quality of life when they receive left ventricular assist devices (LVADs) at an earlier state of disease progression, rather than waiting until they are critically ill from their heart failure, as is currently required to receive an LVAD. This study is taking place at nearly two dozen institutions across the United States.
You may qualify to participate in this important step forward if:
- You have had heart failure for at least one year.
- Your left ventricular ejection fraction is 35% or less.
- If you become tired or short of breath when walking a block or climbing a flight of stairs.
- You are at least 21 years of age.
REVIVE-IT is conducted under an Investigational Device Exemption from the US Food and Drug Administration (IDE G120277) and funded by the National Institutes of Health’s National Heart Lung and Blood Institute (contract number HHSN268201100026C) and by Thoratec Corporation.
Click below for more information